Analyst Price Target is $25.00
▲ +341.70% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for ProPhase Labs in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 341.70% upside from the last price of $5.66.
Current Consensus is
The current consensus among 1 contributing investment analysts is to hold stock in ProPhase Labs.
ProPhase Labs, Inc. is a medical science and technology company. It engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The firm operates through the following business segments: Diagnostic Services and Consumer Products. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.